Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — FY2024 Earnings Presentation
23 slides from Silence Therapeutics's earnings presentation, Feb 27, 2025
Slide 1: Full Year 2024 Results
Exhibit 99.2 Full Year 2024 Results February 27, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation
Slide 3: Company Overview
Company Overview CRAIG TOOMAN Chief Executive Officer 3
Slide 4: Silence Delivered Strong Clinical Results and Pipeline Advancement in 2024
Silence Delivered Strong Clinical Results and Pipeline Advancement in 2024 ZERLASIRAN DIVESIRAN GOLD PLATFORM • ALPACAR-360 Ph. 2 • SANRECO Ph. 1 study • SLN312 (licensed to study delivered positive delivered positive results AstraZeneca) entered results in high Lp(a) in PV Ph. 1 study • Finalized P
Slide 5: 2025: Advancing Clinical Pipeline in Rare Conditions with High Unmet Needs
2025: Advancing Clinical Pipeline in Rare Conditions with High Unmet Needs DIVESIRAN GOLD PLATFORM EXTRA HEPATIC • First-in-class siRNA for PV • SLN548 (complement factor • Advancing programs targeting B) Ph. 1 study start multiple cell types • SANRECO Ph. 1 data anticipated in 2H 2025 presentations
Slide 6: Financial Review and 2025 Guidance
Financial Review and 2025 Guidance RHONDA HELLUMS Chief Financial Officer 6
Slide 7: 2024 Financial Results
2024 Financial Results Financial Results ($ thousands) FY 2024 FY 2023 Revenue $43,258 $31,634 Cost of Sales ($11,810) ($12,867) Research and Development Costs ($67,883) ($56,937) General and Administrative Expenses ($26,884) ($26,222) Operating Loss ($63,319) ($64,383) Net Loss ($45,309) ($54,228)
Slide 8: 2025 Financial Guidance
2025 Financial Guidance FINANCIAL PRIORITIES CASH GUIDANCE • Divesiran for PV Projected Runway • Advancing pipeline in rare conditions Extended into 2027 • Extra-hepatic 8 8
Slide 9: Clinical Update
Clinical Update STEVEN ROMANO, MD Chief R&D Officer 9
Slide 10: Polycythemia Vera (PV): A Rare Blood Cancer We Are Targeting
Polycythemia Vera (PV): A Rare Blood Cancer We Are Targeting • Myeloproliferative neoplasm characterized by the excessive production of red blood cells (RBCs) Treatment goal is o Elevated hematocrit (HCT) is a hallmark of the disease, to control HCT indicating overproduction of RBCs <45% to reduce •
Slide 11: People Living with PV Experience Significant Unmet Needs
People Living with PV Experience Significant Unmet Needs Inconsistent HCT Control Iron Deficiency Disease Burden • Patients with HCT between 45- • Most patients with PV are iron • Patients with elevated HCT often 50% are ~4x more likely to die deficient due to depleted bone require frequent phleboto
Slide 12: Divesiran is a First-in-Class siRNA for PV
Divesiran is a First-in-Class siRNA for PV Divesiran has FDA Fast Track and Orphan Drug Designations in PV 12 12
Slide 13: SANRECO Phase 1 Study of Divesiran in PV Patients
SANRECO Phase 1 Study of Divesiran in PV Patients Open-label, dose-finding study of divesiran in PV patients Design • 21 patients Cohorts • 6 patients at 3 mg/kg, 8 patients at 6 mg/kg and 7 patients at 9 mg/kg • Administered subcutaneously every 6 weeks for four doses Dosing & • 16-week follow-up p
Slide 14: Divesiran Reduced Phlebotomy Frequency in PV Patients
Divesiran Reduced Phlebotomy Frequency in PV Patients Cohort 1 (3mg/kg) Cohort 2 (6mg/kg) Cohort 3 (9mg/kg) 79 Phlebotomies Prior to Dosing, 5 in Treatment Period and 2 in Follow-up; No Well-Controlled Patients (HCT<45% at baseline) Required a Phlebotomy 1. Interim Phase 1 results presented at the A
Slide 15: Divesiran Reduced Hematocrit in PV Patients
Divesiran Reduced Hematocrit in PV Patients Dosing Divesiran Decreased Hematocrit in All Cohorts 1. Interim Phase 1 results presented at the American Society of Hematology (ASH) 2024 Annual Meeting. December 8, 2024. Interim Phase 1 results included 19 PV patients. 2. Orange dotted line 15 15 repres
Slide 16: Divesiran Treatment Produced Sustained Increases in Hepcidin
Divesiran Treatment Produced Sustained Increases in Hepcidin Dosing Divesiran Treatment Induced Hepcidin 1. Interim Phase 1 results presented at the American Society of Hematology (ASH) 2024 Annual Meeting. December 8, 2024. Interim Phase 1 results included 19 PV patients. 2. Orange dotted line repr
Slide 17: Divesiran Demonstrated a Favorable Safety and Tolerability Profile
Divesiran Demonstrated a Favorable Safety and Tolerability Profile • Divesiran was well tolerated with no dose-limiting toxicities • Treatment emergent adverse events (TEAEs) were recorded in 19/21 participants • Majority of TEAEs (84%) were grade 1 • No TEAEs grade > 2 • 52 mild self-limiting injec
Slide 18: SANRECO Phase 2 Study of Divesiran in PV Patients
SANRECO Phase 2 Study of Divesiran in PV Patients Design Randomized, double-blind study of divesiran in up to 40 PV patients • PV diagnosis Key • At least 3 phlebotomies in the last 6 months or 5 in the last year prior to screening Inclusion • Stable dose of cytoreductive agents allowed Criteria • H
Slide 19: The Complement Pathway
The Complement Pathway Complement Pathway(s) CC lassi lassi cal cal Lectin Alternative FP MBL C3(H O 2 Ficolins C1q C1r C3 “tick over” MASP1,2,3 C1s FH C3b FB C2 C4 FD C4b2b C3bBb C3(H O)Bb 2 C3 C3b C3a FB FD C3bBb Inflammatory C3bBb3b signaling Chemoattraction C5 C5a C5b C5b9 Tissue Injury MAC Cell
Slide 20: Phase 1 Study of SLN548 in Healthy Volunteers
Phase 1 Study of SLN548 in Healthy Volunteers Design Randomized, double-blind, placebo-controlled, single-ascending dose study • Approximately 32 healthy volunteers Enrollment • All patients will be vaccinated and receive prophylactic antibiotics as appropriate • 4 cohorts, 8 subjects per cohort Dos
Slide 21: Anticipated 2025 Milestones
Anticipated 2025 Milestones Divesiran – Polycythemia Vera (PV) SANRECO Phase 1 follow-up completion Phase 1 data at medical meetings 2025 SANRECO Phase 2 study full enrollment 4Q 2025 SLN548 – Complement-Mediated Diseases Phase 1 study initiation 2H 2025 21 21
Slide 22: Q&A
Q&A 22
Slide 23: Thank You
} SILENCE THERAPEUTICS > THANK YOU!